EP0306525A1 - Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus - Google Patents

Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus

Info

Publication number
EP0306525A1
EP0306525A1 EP88903550A EP88903550A EP0306525A1 EP 0306525 A1 EP0306525 A1 EP 0306525A1 EP 88903550 A EP88903550 A EP 88903550A EP 88903550 A EP88903550 A EP 88903550A EP 0306525 A1 EP0306525 A1 EP 0306525A1
Authority
EP
European Patent Office
Prior art keywords
insulin
diabetes mellitus
aldose reductase
type
reductase inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP88903550A
Other languages
German (de)
French (fr)
Other versions
EP0306525A4 (en
Inventor
Billie M. York, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Vision LLC
Original Assignee
Alcon Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Laboratories Inc filed Critical Alcon Laboratories Inc
Publication of EP0306525A1 publication Critical patent/EP0306525A1/en
Publication of EP0306525A4 publication Critical patent/EP0306525A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Definitions

  • the present invention relates to the field of diabetes mellitus therapy. More particularly, this invention relates to the use of compounds having aldose reductase inhibiting activity (hereinafter referred to as "aldose reductase inhibitors”) to correct an abnormal metabolic pathway associated with diabetes mellitus, thereby enhancing and/or restoring insulin sensitivity.
  • aldose reductase inhibitors compounds having aldose reductase inhibiting activity
  • diabetes mellitus is used to describe chronic hyperglycemia and the side effects of glucose toxicity.
  • diabetes mellitus There are two general classifications of diabetes mellitus: (1) insulin-dependent (Type I), and (2) noninsul in-dependent (Type II).
  • Type I insulin-dependent
  • Type II noninsul in-dependent
  • the present invention is directed to the treatment of both Type I and Type II diabetes mellitus, particularly Type II.
  • Type I diabetes mellitus is generally attributable to an insulin deficiency.
  • simple insulin deficiency cannot entirely account for the diabetic syndrome seen in Type II diabetes mellitus. This conclusion is supported by the following observations: (1) in many Type II diabetics, insulin deficiency is not present; and (2) even in Type II diabetics who have impaired insulin secretion leading to an insulin deficiency, insulin resistance can be demonstrated to be responsible for their hyperglycemic state.
  • insulin receptor function in Type II diabetes mellitus patients can be modified by sustained, rigorous caloric and/or carbohydrate restriction, oral hypoglycemic drug therapy, insulin injections, and/or physical exercise which results in weight Toss.
  • these therapeutic approaches taken either alone or in combination (i.e., diet, exercise, insulin, and/or oral hypoglycemics), the net overall effect is to lower blood glucose over a sustained time.
  • induced hypoglycemia This effect is called “induced hypoglycemia.”
  • the following articles may be referred to for further background in connection with known therapeutic methods of inducing hypoglycemia, and the resulting modification of insulin receptor function: Savag et al., "Diet induced improvement of abnormalities in insulin and glucagon secretion and in insulin receptor binding in diabetes mellitus," Diabetes Care, Vol. 5, pages 999-1007 (1979); Beck-Nielsen et al., “Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese patients following treatment with glibencl amide,” Acta Endocrinology, Vol.
  • Type II diabetes mellitus It follows that frequent episodes of hyperglycemia in adults induced, for example, by a high calorie diet and lack of exercise, will eventually diminish insulin sensitivity and induce Type II diabetes mellitus.
  • the aforementioned chronic process may be described as an insidious change in the glucose "set point" induced by improper life style and aging.
  • the biochemical mechanism underlying a loss of insulin sensitivity and concomitant changes in glucose metabolism in connection with Type II diabetes mellitus is believed to involve the energetically expensive enzymatic conversion of the aldose sugar, glucose, to sorbitol at the cost of NADPH. This loss of NADPH co-factor substantially suppresses the very dynamic reduction of oxidized glutathione into reduced glutathione.
  • Reduced glutathione is believed to be involved in maintaining normal insulin receptor function at the target cells. It has been previously demonstrated that insulin release in response to glucose is related to the redox state of islet cell thiols, and that reduced glutathione enhances the capacity of glucose to induce insulin release. See Hallman et al., "Stimulation of insulin release by thiols,” Biochem. Biophys. Acta, Vol. 392, pages 101-109 (1975); and Ammon et al., "Cysteine analogues potentiate glucose-induced insulin release in vitro," Diabetes, Vol. 35, pages 1390-1396 (1986), respectively.
  • the present invention is directed to enhancing insulin sensitivity at or within target tissues by administering one or more aldose reductase inhibitors to patients who are either afflicted with diabetes mellitus or predisposed to acquiring this disease.
  • An appropriate aldose rethictase inhibitor regimen will prevent and/or reverse loss of insulin sensitivity.
  • This treatment with aldose reductase inhibitors results in a gradual decrease in insulin resistance by enhancing normal insulin receptor function at the target cells.
  • This positive effect on insulin receptor function is believed to be the result of normalization of the redox state of the affected cells (i.e., normalization of the conversion of intracellular oxidized glutathione to reduced glutathione); more specifically, the enhancement of insulin receptor sensitivity is believed to result directly from increased cellular levels of reduced glutathione.
  • glutathione metabolism is the indirect result of interruption of an abnormal metabolic pathway by aldose reductase inhibitors. More particularly, diabetes mellitus is believed to involve an abnormal metabolic pathway wherein the aldose sugar, glucose, is converted to sorbitol at the expense of NADPH. This loss of NADPH affects the cellular redox state in a manner such that the conversion of oxidized glutathione to reduced glutathione is decreased, thereby decreasing the amount of reduced glutathione available at the insulin receptors. Reduced glutathione either directly or indirectly (e.g., via a transferase) maintains the insulin receptor in a reduced thiol state.
  • An insulin receptor active site must be in a reduced thiol state in order for a mixed disulfide bond or an activated complex to form between insulin and the insulin receptor.
  • Aldose reductase inhibitors prevent the above-described depletion of NADPH and resulting decrease in cellular reduced glutathione levels and thiol reduction potential by inhibiting glucose reducing enzymes, such as aldose reductase and L-hexonate dehydrogenase, and thereby promote the binding of both endogenous and exogenous insulin to insulin receptor sites.
  • the methods of the present invention are applicable to treatment of both Type I and Type II diabetes mellitus, and to reversal and prevention of Type II diabetes mellitus, and comprise administering a therapeutically effective amount of an aldose reductase inhibitor.
  • the administration of an appropriate aldose reductase inhibitor regimen effectively lowers blood glucose levels in Type I and Type II diabetes mellitus patients by enhancing the action of endogenous and exogenous insulin.
  • the amount of insulin required to maintain a normal blood glucose level may be reduced.
  • a similar result will be expected in Type II diabetes mellitus patients who are receiving insulin therapy.
  • Type II patients receiving a combination of insulin and an aldose reductase inhibitor it may be possible to discontinue insulin use after a relatively short course of therapy (e.g., several weeks) with this combination, and to maintain a normal blood glucose level thereafter using only aldose reductase inhibitor therapy.
  • the present invention also provides a method of preventing, or at least retarding, the onset of Type II diabetes mellitus in patients who are predisposed to acquiring this disease.
  • a fasting blood glucose level of greater than 140 mg of glucose per deciliter of blood is generally associated with a clinical diagnosis of Type II diabetes mellitus.
  • a patient having a fasting blood glucose level of greater than 100 mg per deciliter of blood but less than 140 mg per deciliter is considered to be "hyperglycemic.”
  • aldose dose reductase inhibitors which may be employed in the present invention comprise any compound having aldose reductase inhibiting activity which is therapeutically effective in enhancing insulin sensitivity, and is safe for use in humans and other mammals.
  • Aldose reductase inhibitors which are particularly suitable for use in the method of the present invention are disclosed in commonly assigned U.S. Patent Nos. 4,537,892; 4,436,745; and 4,438,272.
  • the following patents disclose additional examples of aldose reductase inhibitors which may be used in the present invention: U.S. Patent Nos. 3,821,383; 4,117,230; 4,130,714; and 4,181,728.
  • the entire contents of the abovecited patents are hereby incorporated by reference in the present specification.
  • the following compounds represent particularly preferred aldose reductase inhibitors: a.
  • [3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-yl]acetic acid also called “STATIL®”
  • patients afflicted with diabetes mellitus and patients predisposed to acquiring diabetes mellitus are treated with one or- more aldose reductase inhibitors in an amount effective to enhance insulin sensitivity (i.e., a "therapeutically effective” amount).
  • the aldose reductase inhibitor(s) may be administered to the patient by means of a variety of dosage forms and routes of administration, as will be readily appreciated by those skilled in the art. Oral administration is generally preferred, but topical administration and administration by injection may be found preferable in some instances.
  • Dosage regimens i.e., amount and frequency

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un procédé d'augmentation de la sensibilité de mammifères (par exemple, d'êtres humains) à l'insuline se fonde sur l'utilisation d'inhibiteurs de la réductase aldose afin de rétablir et de maintenir des taux réduits de glutathione intracellulaire, stimulant ainsi la formation de liaisons mixtes bisulphures avec les récepteurs d'insuline.A method of increasing the sensitivity of mammals (e.g., humans) to insulin is based on the use of aldose reductase inhibitors to restore and maintain reduced levels of stimulating intracellular glutathione thus the formation of mixed bisulphide bonds with insulin receptors.

Description

USE OF ALDOSE REDUCTASE INHIBITORS TO ENHANCE INSULIN SENSITIVITY IN DIABETES MELLITUS
Background of the Invention
The present invention relates to the field of diabetes mellitus therapy. More particularly, this invention relates to the use of compounds having aldose reductase inhibiting activity (hereinafter referred to as "aldose reductase inhibitors") to correct an abnormal metabolic pathway associated with diabetes mellitus, thereby enhancing and/or restoring insulin sensitivity.
The term "diabetes mellitus" is used to describe chronic hyperglycemia and the side effects of glucose toxicity. There are two general classifications of diabetes mellitus: (1) insulin-dependent (Type I), and (2) noninsul in-dependent (Type II). The present invention is directed to the treatment of both Type I and Type II diabetes mellitus, particularly Type II.
The above-cited classifications of diabetes mellitus are based on the role insulin plays in the disease state. Type I diabetes mellitus is generally attributable to an insulin deficiency. In contrast, it is clear that simple insulin deficiency cannot entirely account for the diabetic syndrome seen in Type II diabetes mellitus. This conclusion is supported by the following observations: (1) in many Type II diabetics, insulin deficiency is not present; and (2) even in Type II diabetics who have impaired insulin secretion leading to an insulin deficiency, insulin resistance can be demonstrated to be responsible for their hyperglycemic state. Reference is made to the following articles for further background in this regard: Reaven et al., "Nonketotic diabetes mellitus: insulin deficiency or insulin resistance?", American Journal of Medicine, Vol. 60, page 80 (1976); Alford et al., "The significance and interpretation of mildly abnormal oral glucose tolerance," Diabetoloqia, Vol. 7, page 173 (1971); and DeFronzo et al., "Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes," Journal of Clinical Investigation, Vol. 63, page 939 (1979). It is known that the insulin resistance associated with Type II diabetes mellitus patients and consequent hyperglycemia can be partially reversed with frequent insulin injections. Moreover, it is known that insulin receptor function in Type II diabetes mellitus patients can be modified by sustained, rigorous caloric and/or carbohydrate restriction, oral hypoglycemic drug therapy, insulin injections, and/or physical exercise which results in weight Toss. With these therapeutic approaches, taken either alone or in combination (i.e., diet, exercise, insulin, and/or oral hypoglycemics), the net overall effect is to lower blood glucose over a sustained time. This effect is called "induced hypoglycemia." The following articles may be referred to for further background in connection with known therapeutic methods of inducing hypoglycemia, and the resulting modification of insulin receptor function: Savag et al., "Diet induced improvement of abnormalities in insulin and glucagon secretion and in insulin receptor binding in diabetes mellitus," Diabetes Care, Vol. 5, pages 999-1007 (1979); Beck-Nielsen et al., "Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese patients following treatment with glibencl amide," Acta Endocrinology, Vol. 90, pages 103-112 (1979); Beck-Nielsen et al., "Increased insulin sensitivity and cellular insulin binding in obese diabetes following treatment with glibenclamide," Acta Endocrinology, Vol. 90, pages 451-462 (1979); Rizkalla et al., "Insulin receptor changes in Type II diabetes after short-term insulin treatment," Horm. Metabol. Res., Vol. 17, pages 512-517 (1985); Scarlett et al., "Insulin treatment reverses the insulin resistance of Type II diabetes mellitus," Diabetes Care, Vol. 5, pages 353-363 (1982); and Selig, "Hypoglycemia during prolonged exercise in normal men," Endocrinology, Vol. 1983, pages 209-212 (1983). While applicant is not bound by any theory, it is believed that inducing hypoglycemia will, in time, increase insulin sensitivity in
Type II diabetes mellitus. It follows that frequent episodes of hyperglycemia in adults induced, for example, by a high calorie diet and lack of exercise, will eventually diminish insulin sensitivity and induce Type II diabetes mellitus. The aforementioned chronic process may be described as an insidious change in the glucose "set point" induced by improper life style and aging. The biochemical mechanism underlying a loss of insulin sensitivity and concomitant changes in glucose metabolism in connection with Type II diabetes mellitus is believed to involve the energetically expensive enzymatic conversion of the aldose sugar, glucose, to sorbitol at the cost of NADPH. This loss of NADPH co-factor substantially suppresses the very dynamic reduction of oxidized glutathione into reduced glutathione. Reduced glutathione is believed to be involved in maintaining normal insulin receptor function at the target cells. It has been previously demonstrated that insulin release in response to glucose is related to the redox state of islet cell thiols, and that reduced glutathione enhances the capacity of glucose to induce insulin release. See Hallman et al., "Stimulation of insulin release by thiols," Biochem. Biophys. Acta, Vol. 392, pages 101-109 (1975); and Ammon et al., "Cysteine analogues potentiate glucose-induced insulin release in vitro," Diabetes, Vol. 35, pages 1390-1396 (1986), respectively. It has also been suggested that metabolic changes in cellular glutathione in diabetes mellitus cause other reversible thiol-disulfide regulated metabolic changes which result in a net increase in cellular gluconeogenesis. See Ziegler, "Role of reversible oxidation-reduction of enzyme thiol-disulfide in metabolic regulation," Annu. Rev. Biochem., Vol. 54, pages 305-329 (1984).
Summary of the Invention
The present invention is directed to enhancing insulin sensitivity at or within target tissues by administering one or more aldose reductase inhibitors to patients who are either afflicted with diabetes mellitus or predisposed to acquiring this disease. An appropriate aldose rethictase inhibitor regimen will prevent and/or reverse loss of insulin sensitivity. This treatment with aldose reductase inhibitors results in a gradual decrease in insulin resistance by enhancing normal insulin receptor function at the target cells. This positive effect on insulin receptor function is believed to be the result of normalization of the redox state of the affected cells (i.e., normalization of the conversion of intracellular oxidized glutathione to reduced glutathione); more specifically, the enhancement of insulin receptor sensitivity is believed to result directly from increased cellular levels of reduced glutathione.
While applicant is not bound by any theory, it is believed that the above-cited normalization of glutathione metabolism is the indirect result of interruption of an abnormal metabolic pathway by aldose reductase inhibitors. More particularly, diabetes mellitus is believed to involve an abnormal metabolic pathway wherein the aldose sugar, glucose, is converted to sorbitol at the expense of NADPH. This loss of NADPH affects the cellular redox state in a manner such that the conversion of oxidized glutathione to reduced glutathione is decreased, thereby decreasing the amount of reduced glutathione available at the insulin receptors. Reduced glutathione either directly or indirectly (e.g., via a transferase) maintains the insulin receptor in a reduced thiol state. An insulin receptor active site must be in a reduced thiol state in order for a mixed disulfide bond or an activated complex to form between insulin and the insulin receptor. Aldose reductase inhibitors prevent the above-described depletion of NADPH and resulting decrease in cellular reduced glutathione levels and thiol reduction potential by inhibiting glucose reducing enzymes, such as aldose reductase and L-hexonate dehydrogenase, and thereby promote the binding of both endogenous and exogenous insulin to insulin receptor sites.
The methods of the present invention are applicable to treatment of both Type I and Type II diabetes mellitus, and to reversal and prevention of Type II diabetes mellitus, and comprise administering a therapeutically effective amount of an aldose reductase inhibitor. The administration of an appropriate aldose reductase inhibitor regimen effectively lowers blood glucose levels in Type I and Type II diabetes mellitus patients by enhancing the action of endogenous and exogenous insulin. As the result of the administration of an appropriate aldose reductase inhibitor regimen to a patient afflicted with Type I diabetes mellitus, the amount of insulin required to maintain a normal blood glucose level may be reduced. A similar result will be expected in Type II diabetes mellitus patients who are receiving insulin therapy. In Type II patients receiving a combination of insulin and an aldose reductase inhibitor, it may be possible to discontinue insulin use after a relatively short course of therapy (e.g., several weeks) with this combination, and to maintain a normal blood glucose level thereafter using only aldose reductase inhibitor therapy.
The present invention also provides a method of preventing, or at least retarding, the onset of Type II diabetes mellitus in patients who are predisposed to acquiring this disease. A fasting blood glucose level of greater than 140 mg of glucose per deciliter of blood is generally associated with a clinical diagnosis of Type II diabetes mellitus. In contrast, a patient having a fasting blood glucose level of greater than 100 mg per deciliter of blood but less than 140 mg per deciliter is considered to be "hyperglycemic." There is a further class of patients who are not yet diabetic in a clinical sense, but are predisposed to acquiring diabetes. These patients are referred to as "latent" or "chemical" diabetics. In accordance with the present invention, it is possible to retard the progression of the underlying disease state in both patients who are hyperglycemic and patients who may be identified as latent or chemical diabetics, thereby preventing the progression of the disease state to a point at which the patients would be clinically diagnosed as having Type II diabetes mellitus. This prevention or prophylaxis is achieved by enhancing the action of endogenous insulin, as explained above.
Detailed Description of the Invention
The aldose dose reductase inhibitors which may be employed in the present invention comprise any compound having aldose reductase inhibiting activity which is therapeutically effective in enhancing insulin sensitivity, and is safe for use in humans and other mammals. Aldose reductase inhibitors which are particularly suitable for use in the method of the present invention are disclosed in commonly assigned U.S. Patent Nos. 4,537,892; 4,436,745; and 4,438,272. The following patents disclose additional examples of aldose reductase inhibitors which may be used in the present invention: U.S. Patent Nos. 3,821,383; 4,117,230; 4,130,714; and 4,181,728. The entire contents of the abovecited patents are hereby incorporated by reference in the present specification. The following compounds represent particularly preferred aldose reductase inhibitors: a.
7,9-difluoro-2-methylspiro(5H-indeno [1,2-b]pyridin-5,3'-pyrolidine)- 2',5'-dione; b.
7,9-difluoro-2-methylspiro(5H-indeno [1,2-b]pyridin-5,4' imidazolidine)- 2',5,-dione; c.
2,7-difluoro-4-methylspiro(9H-fluoren-9,4'-imidazolidine)-2',5'dione; d.
7-fluoro-2-methylspiro(5H-indeno[1,2-b]-pyridin-5,4' imidazolidine)-2',5'-dione;
e.
2,7-difluoro-4-methylthiospiro(9H-fluoren-9,4'-imidazolidine)-2',5'-dione; f.
7,9-difluoro-2-methylthιospiro(5H-ideno [1,2-b]pyridin-5,4'- imidazolidine)-2',5'-dione;
2,5,7-trifluoro-4-methylspiro(9H-fluoren-9,4'-imidazolidine)-2',5'-dione; h.
2,5,7-trifluoro-4-methylthiospiro(9H-fluoren-9,4'-imidazolidine)-2',5'-dione;
i.
7-methylthiospiro(5H-ideno[1,2-b]pyridin-5,3'-pyrolidine)-2',5'-dione; j.
2,7-difluorospiro(9H-fluoren-9,4' imidazolidin)-2',5'-dione;
2,7-difluorospiro(9H-fluoren-9,5'-oxazolidine)-2'5'dione; 2,7-difluorospiro(9H-fluoren-9,3'-pyrolidine;)-2',5'-dione;
m.
(S)-6-fluorospiro[chroman-4,4'-imidazolidine]-2',5'dione (also called "SORBINIL®"); n.
N-[[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-n- methylglycine (also called "TOLRESTAT®"); and
o .
[3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-yl]acetic acid (also called "STATIL®"). In accordance with the present invention, patients afflicted with diabetes mellitus and patients predisposed to acquiring diabetes mellitus are treated with one or- more aldose reductase inhibitors in an amount effective to enhance insulin sensitivity (i.e., a "therapeutically effective" amount). The aldose reductase inhibitor(s) may be administered to the patient by means of a variety of dosage forms and routes of administration, as will be readily appreciated by those skilled in the art. Oral administration is generally preferred, but topical administration and administration by injection may be found preferable in some instances. Dosage regimens (i.e., amount and frequency) will be determined by the clinician based on factors such as the patient's physical condition and the duration of action of the pharmaceutical composition employed.

Claims

What is claimed is:
1. A method of enhancing insulin sensitivity in a patient afflicted with diabetes mellitus, which comprises administering a therapeutically effeltive amount of an aldose reductase inhibitor to the patient.
2. A method of preventing or retarding the onset of Type II diabetes mellitus in a patient predisposed to acquiring this condition, which comprises administering a therapeutically effective amount of an aldose reductase inhibitor to the patient.
EP19880903550 1987-03-20 1988-03-18 Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus Withdrawn EP0306525A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2851287A 1987-03-20 1987-03-20
US28512 1987-03-20

Publications (2)

Publication Number Publication Date
EP0306525A1 true EP0306525A1 (en) 1989-03-15
EP0306525A4 EP0306525A4 (en) 1991-04-24

Family

ID=21843865

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19880903550 Withdrawn EP0306525A4 (en) 1987-03-20 1988-03-18 Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus

Country Status (6)

Country Link
EP (1) EP0306525A4 (en)
JP (1) JPH01503460A (en)
KR (1) KR890700346A (en)
AU (1) AU598366B2 (en)
CA (1) CA1310269C (en)
WO (1) WO1988006887A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
KR100343944B1 (en) * 2001-02-14 2002-07-24 주식회사 에이.비.아이 Composition of L-2-oxothiazolidine-4-carboxylic acid or its saits as non-insulin dependent diabetes therapeutic agent

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4436745A (en) * 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
US4438272A (en) * 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
US4537892A (en) * 1983-09-14 1985-08-27 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
JPS6178725A (en) * 1984-09-20 1986-04-22 アメリカン・ホーム・プロダクツ・コーポレイシヨン Stabilized tolrestat rotation isomer composition
US4600717A (en) * 1984-04-11 1986-07-15 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in ophthalmic wound healing
US4609663A (en) * 1984-09-11 1986-09-02 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in glaucoma therapy
US4864028A (en) * 1983-09-14 1989-09-05 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4147797A (en) * 1978-08-11 1979-04-03 Pfizer Inc. Spiro-furanohydantoin derivatives
US4251258A (en) * 1978-09-29 1981-02-17 Monsanto Company N-(Substituted carbonyl) derivatives of N-phosphinylmethylglycinates and the herbicidal use thereof
US4226875A (en) * 1979-04-02 1980-10-07 Pfizer Inc. Novel spiro-oxazolidinediones
US4235911A (en) * 1979-06-13 1980-11-25 Pfizer Inc. Hydantoin derivatives
US4254108A (en) * 1979-11-08 1981-03-03 Ayerst, Mckenna & Harrison Inc. Thioxo-1H-benz[de]isoquinoline-2(3H)-acetic acid derivatives and antidiabetic use thereof
US4430337A (en) * 1982-06-23 1984-02-07 Pfizer Inc. Alicyclic substituted oxazolidine-2,4-diones having hypoglycemic activity
US4604406A (en) * 1984-11-16 1986-08-05 Ayerst, Mckenna & Harrison, Inc. N-[6-methoxy-5-(perfluoroalkyl)-1-naphtholyl]-N-methylglycines and their thionaphthoyl analogs
US4575507A (en) * 1985-05-29 1986-03-11 Pfizer Inc. Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4436745A (en) * 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
US4438272A (en) * 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
US4537892A (en) * 1983-09-14 1985-08-27 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
US4864028A (en) * 1983-09-14 1989-09-05 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives
US4600717A (en) * 1984-04-11 1986-07-15 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in ophthalmic wound healing
US4609663A (en) * 1984-09-11 1986-09-02 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in glaucoma therapy
JPS6178725A (en) * 1984-09-20 1986-04-22 アメリカン・ホーム・プロダクツ・コーポレイシヨン Stabilized tolrestat rotation isomer composition

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
Biochimica et Biophysica Acta, Vol. 870, 1986, pages 302-311, Elsevier Science Publishers B.V. (Biomedical Division); S.K. SRIVASTAVA et al.: "Hyperglycemia-induced activation of human erythrocyte aldose reductase and alterations in kinetic properties", Abstract. *
Chem. Pharm. Bull., Vol. 32, No. 5, 1984, pages 2030-2032; I. MIWA et al.: "Hypoglycemic activity of aldose reductase inhibitor, 1 (p-bromophenyl) sulfonyl hydantoin", whole article. *
CHEMICAL ABSTRACTS, Vol. 105, No. 11, 15th September 1986, page 337, Abstract No. 102604d, Columbus, Ohio, US; & JP,A,61 078 725 (AMERICAN HOME PRODUCTS CORP.) 22-04-1986, whole Abstract. *
Exp. Eye Res., Vol. 46, 1988, pages 517-530, Academic Press Ltd; M.F. LOU et al.: "Glutathione depletion in the lens of galactosemic and diabetic rats", whole article. *
Horm. Metab. Res., Vol. 10, 1978, pages 280-282, Georg Thieme Publishers; W. LIPPMANN et al.: "Effect of alrestatin on arginine-induced secretion of glycagon and insulin in the rat", Summary. *
Metabolism, Vol. 34, No. 10, October 1985, pages 885-892, Grune & Stratton, Inc.; N. SIMARD-DUQUESNE et al.: "The effects of a new aldose reductase inhibitor (Tolrestat) in galactosemic and diabetic rats", whole article. *
Metabolism, Vol. 34, No. 4, April 1985, pages 336-344, Grune & Stratton, Inc.; D. STRIBLING et al.: "Properties of ICI 128,436, a novel aldose reductase inhibitor, and its effects on diabetic complications in the rat", Abstract. *
Metabolism, Vol. 35, No. 4, suppl. 1, April 1986, pages 83-92, Grune & Stratton, Inc.; J.B. JASPAN et al.: "Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes", Abstract. *
Metabolism, Vol. 36, No. 5, May 1987, pages 486-490, Grune & Stratton, Inc.; B. WALKER GRIFFIN et al.: "Effects of two new aldose reductase inhibitors, AL-1567 and AL-1576, in diabetic rats", whole article. *
Pharmacology, Vol. 32, 1986, pages 52-60; A. BEYER-MEARS et al.: "Diminished proteinuria in diabetes mellitus by sorbinil, an aldose reductase inhibitor", Abstract. *
See also references of WO8806887A1 *

Also Published As

Publication number Publication date
CA1310269C (en) 1992-11-17
WO1988006887A1 (en) 1988-09-22
AU598366B2 (en) 1990-06-21
AU1549088A (en) 1988-10-10
KR890700346A (en) 1989-04-24
JPH01503460A (en) 1989-11-22
EP0306525A4 (en) 1991-04-24

Similar Documents

Publication Publication Date Title
Christlieb et al. Vascular reactivity to angiotensin II and to norepinephrine in diabetic subjects
Horton et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
Brunzell et al. Effect of a fat free, high carbohydrate diet on diabetic subjects with fasting hyperglycemia
DeFronzo et al. Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects
Glaser et al. Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes
Sönksen et al. Growth hormone and diabetes mellitus: a review of sixty-three years of medical research and a glimpse into the future?
US6207714B1 (en) Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid
Anderson Effect of carbohydrate restriction and high carbohydrate diets on men with chemical diabetes
CA2073873C (en) Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders
KR20010020497A (en) Therapeutic method for management of diabetes mellitus
EP0808164B1 (en) Use of prolactin modulators and diet for the manufacture of a medicament for the treatment of obesity
US5430065A (en) Therapeutical method for enhancing peripheral glucose utilization in a non-insulin-dependent diabetic patient
De Vries et al. Characteristic renal excretion patterns in response to physiological, pathological and pharmacological stimuli
US6787163B2 (en) Therapeutic treatment for blood sugar regulation
Mathieu The scientific evidence: vildagliptin and the benefits of islet enhancement
Romanelli et al. Short-term administration of captopril and nifedipine and exercise-induced albuminuria in normotensive diabetic patients with early-stage nephropathy
EP0306525A1 (en) Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes mellitus
US20140329844A1 (en) Method of restoring the incretin effect
Shear Orthostatic hypotension: treatment with sodium chloride and sodium retaining steroid hormones
FINCHAM et al. Use of phenytoin serum levels in a case of status epilepticus
TWI248814B (en) Compositions comprising D-chiro inositol and lipid lowering compounds
RU2750523C1 (en) Method of treatment of elderly patients with type 2 diabetes mellitus
Yuan Effect of Glipizide on non-insulin-dependent diabetes mellitus
Gupta et al. Glucose homeostasis and drugs acting on CNS: Interactions with antidiabetic agents
Lahtela Effect of Long‐Term Anticonvulsant Therapy on Glucose Metabolism in Humans

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19890519

A4 Supplementary search report drawn up and despatched

Effective date: 19910306

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

DA4 Supplementary search report drawn up and despatched (deleted)
RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 19910805

17Q First examination report despatched

Effective date: 19920610

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19930511